These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
95 related articles for article (PubMed ID: 21752037)
1. In vitro removal of beta-2-microglobulin from uremic blood with an immunoadsorption wall. Yang TH; Lin BJ; Ma YL; Chou KJ Artif Organs; 2012 Jan; 36(1):78-86. PubMed ID: 21752037 [TBL] [Abstract][Full Text] [Related]
2. Dialysis related amyloidosis: a disease of chronic retention and inflammation? Floege J; Schäffer J; Koch KM; Shaldon S Kidney Int Suppl; 1992 Oct; 38():S78-85. PubMed ID: 1405384 [TBL] [Abstract][Full Text] [Related]
4. Assessment of the stability of an immunoadsorbent for the extracorporeal removal of Beta-2-microglobulin from blood. Daniels CM; Woolverton EM; Sprague SM; Ameer GA Blood Purif; 2005; 23(4):287-97. PubMed ID: 15942167 [TBL] [Abstract][Full Text] [Related]
5. New ligand coupling procedure for formation of an immunoadsorption wall. Yang TH; Feng CL ASAIO J; 2007; 53(2):201-6. PubMed ID: 17413561 [TBL] [Abstract][Full Text] [Related]
7. Serum beta 2-microglobulin concentration in dialysis patients: importance of intrinsic renal function. McCarthy JT; Williams AW; Johnson WJ J Lab Clin Med; 1994 Apr; 123(4):495-505. PubMed ID: 8144998 [TBL] [Abstract][Full Text] [Related]
8. Role of uremic and endothelial factors in the development of beta 2-microglobulin amyloidosis. Nakashima Y; Akizawa T; Nagai T; Koshikawa S Kidney Int Suppl; 1993 Jun; 41():S88-95. PubMed ID: 8320954 [TBL] [Abstract][Full Text] [Related]
9. Molecular mechanisms underlying uremic toxin-related systemic disorders in chronic kidney disease: focused on β Yamamoto S Clin Exp Nephrol; 2019 Feb; 23(2):151-157. PubMed ID: 29869756 [TBL] [Abstract][Full Text] [Related]
10. [Kidney and bone update : the 5-year history and future of CKD-MBD. Treatment for dialysis-related amyloidosis update]. Yamamoto S; Kazama JJ; Narita I Clin Calcium; 2012 Jul; 22(7):1089-98. PubMed ID: 22750942 [TBL] [Abstract][Full Text] [Related]
11. Long-term complications of dialysis: pathogenic factors with special reference to amyloidosis. Gejyo F; Homma N; Arakawa M Kidney Int Suppl; 1993 Jun; 41():S78-82. PubMed ID: 8320951 [TBL] [Abstract][Full Text] [Related]
12. Statistical and parametric analysis of beta-2-microglobulin removal from uremic patients in high flux hemodialysis. Lee CJ; Hsiong CH; Chang YL; Cheng CH; Lian JD ASAIO J; 1994; 40(1):62-6. PubMed ID: 8186494 [TBL] [Abstract][Full Text] [Related]
13. Modification of beta 2m with advanced glycation end products as observed in dialysis-related amyloidosis by 3-DG accumulating in uremic serum. Niwa T; Katsuzaki T; Momoi T; Miyazaki T; Ogawa H; Saito A; Miyazaki S; Maeda K; Tatemichi N; Takei Y Kidney Int; 1996 Mar; 49(3):861-7. PubMed ID: 8648931 [TBL] [Abstract][Full Text] [Related]
14. Convective therapies for removal of middle molecular weight uremic toxins in end-stage renal disease: a review of the evidence. Thomas G; Jaber BL Semin Dial; 2009; 22(6):610-4. PubMed ID: 20017830 [TBL] [Abstract][Full Text] [Related]
15. First clinical experience with an adjunctive hemoperfusion device designed specifically to remove beta(2)-microglobulin in hemodialysis. Ronco C; Brendolan A; Winchester JF; Golds E; Clemmer J; Polaschegg HD; Muller TE; La Greca G ; Levin NW Blood Purif; 2001; 19(2):260-3. PubMed ID: 11150821 [No Abstract] [Full Text] [Related]